Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Q Sun, Z Hong, C Zhang, L Wang, Z Han… - Signal transduction and …, 2023 - nature.com
Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
DNA repair deficiency regulates immunity response in cancers: molecular mechanism and approaches for combining immunotherapy
Y Xu, S Nowsheen, M Deng - Cancers, 2023 - mdpi.com
Simple Summary DNA repair pathways play a crucial role in maintaining the stability of a
cell's genetic material. When these pathways are defective, it can lead to genomic instability …
cell's genetic material. When these pathways are defective, it can lead to genomic instability …
A carrier-free supramolecular nano-twin-drug for overcoming irinotecan-resistance and enhancing efficacy against colorectal cancer
M Yuan, T Chen, L **, P Zhang, L **e, S Zhou… - Journal of …, 2023 - Springer
Irinotecan (Ir) is commonly employed as a first-line chemotherapeutic treatment for colorectal
cancer (CRC). However, tremendous impediments remain to be addressed to surmount …
cancer (CRC). However, tremendous impediments remain to be addressed to surmount …
RHNO1: at the crossroads of DNA replication stress, DNA repair, and cancer
N Jirapongwattana, SF Bunting, DR Ronning, G Ghosal… - Oncogene, 2024 - nature.com
The DNA replication stress (DRS) response is a crucial homeostatic mechanism for
maintaining genome integrity in the face of intrinsic and extrinsic barriers to DNA replication …
maintaining genome integrity in the face of intrinsic and extrinsic barriers to DNA replication …
[HTML][HTML] DNA damage response-related signatures characterize the immune landscape and predict the prognosis of HCC via integrating single-cell and bulk RNA …
H Li, Y Shi, Y Li, S Wu, R Yang, Q Liu, L Sun - International …, 2024 - Elsevier
Background The occurrence and progression of hepatocellular carcinoma (HCC) are
significantly affected by DNA damage response (DDR). Exploring DDR-related biomarkers …
significantly affected by DNA damage response (DDR). Exploring DDR-related biomarkers …
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
X Su, J Li, X Xu, Y Ye, C Wang, G Pang, W Liu… - Journal of Translational …, 2024 - Springer
Although immune checkpoint inhibitors (anti-PD-1 antibody, anti-PD-L1 antibody, and anti-
CTLA-4 antibody) have displayed considerable success in the treatment of malignant …
CTLA-4 antibody) have displayed considerable success in the treatment of malignant …
The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer
D **e, B Jiang, S Wang, Q Wang, G Wu - Frontiers in Cell and …, 2023 - frontiersin.org
Urologic cancers such as kidney, bladder, prostate, and uroepithelial cancers have recently
become a considerable global health burden, and the response to immunotherapy is limited …
become a considerable global health burden, and the response to immunotherapy is limited …
First-in-Human study of the ataxia telangiectasia and rad3-related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors
TA Yap, AW Tolcher, R Plummer, JK Mukker… - Clinical Cancer …, 2024 - AACR
Abstract Purpose: Tuvusertib (M1774) is a potent, selective, orally administered ataxia
telangiectasia and Rad3-related (ATR) protein kinase inhibitor. This first-in-human study …
telangiectasia and Rad3-related (ATR) protein kinase inhibitor. This first-in-human study …
Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
Immune checkpoint inhibitors (ICI) have achieved unprecedented clinical success in cancer
treatment. However, drug resistance to ICI therapy is a major hurdle that prevents cancer …
treatment. However, drug resistance to ICI therapy is a major hurdle that prevents cancer …
Pancancer analysis of the prognostic and immunological role of FANCD2: a potential target for carcinogenesis and survival
Z Zhao, R Wang, R Wang, J Song, F Ma, H Pan… - BMC medical …, 2024 - Springer
Recent evidence has shed light on the significant role of FANCD2 in cancer initiation,
development, and progression. However, a comprehensive pan-cancer analysis of FANCD2 …
development, and progression. However, a comprehensive pan-cancer analysis of FANCD2 …